Australia's most trusted
source of pharma news
Tuesday, 03 March 2026
Posted 2 March 2026 PM
A "perfect storm" has shortened the exclusivity period innovative pharmaceuticals enjoy in Australia while discouraging pharmas from preventing the launch of infringing products.
A seismic shift hit the industry last December when the Full Federal Court ruled a patent term extension for Otsuka's Abilify Maintena had been wrongly granted because patents based on formulations cannot be extended, and that ruling affects a vast swath of pharmaceutical products.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.